A prospective, interventional clinical study to evaluate the safety and efficacy of Liv.52 DS in the management of non-alcoholic fatty liver disease
DOI:
https://doi.org/10.15584/ejcem.2021.2.3Keywords:
ALT/AST, fatty liver, fibrosis, non-alcoholic fatty liver diseaseAbstract
Introduction. Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other than alcohol use.
Aim. To evaluate the clinical efficacy and safety of Liv.52 DS tablets in the management of NAFLD.
Material and methods. Prospective, interventional clinical study conducted on 60 patients of both sex, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory test, ultrasound findings and those willing to give informed consent. All patients received Liv.52 DS at a dose of 2 tablets twice daily for 2 months. All patients were evaluated at baseline, end of 1st month, and end of 2nd month for liver function tests, hepatomegaly by ultrasound, NAFLD Fibrosis Score, lipid profile, hematology and biochemical investigations.
Results. Study data was analyzed with GraphPad Prism Software Version 6.07. Data of those patients who completed the study was considered for analysis. Significant improvement in hepatomegaly, liver enzymes was observed. NAFLD fibrosis score revealed no progression of liver fibrosis due to NAFLD during the study period. No abnormal lab values were recorded and there were no adverse events reported during the study.
Conclusion. Study concludes that Liv.52 DS is safe and beneficial in individuals suffering from NAFLD.
Downloads
References
National Institute of Diabetes and Digestive and Kidney Diseases. https://en.wikipedia.org/wiki/National_Institute_of_Diabetes_and_Digestive_and_Kidney_Diseases last edited on November 2016. Accessed 7 November 2018.
Iser D, Ryan M. Fatty liver disease- a practical guide for GPs. Aust Fam Physician. 2013;42(7):444-447.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat. Rev. Gastroenterol Hepatol. 2016;13(4):196–205.
Wilfred de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008:104–112.
Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5:211–218.
Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205-214.
Calzadilla Bertot L, Adams LA. The Natural Course of Non-alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17(5):774.
Younossi ZM, Stepanova M, Negro F, et al. Non-alcoholic fatty liver disease in lean individuals in
Gu Y, Lambert JD. Modulation of metabolic syndrome-related inflammation by cocoa. Mol Nutr Food Res. 2013;57:948-961.
Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med (London). 2011;11:176-178.
Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven- year prospective follow-up. J Hepatol. 2012;56:1145-1151.
Woo S, Yoon M, Kim J, et al. The anti-angiogenic herbal extract from Melissa officinalis inhibits adipogenesis in 3T3-L1 adipocytes and suppresses adipocyte hypertrophy in high fat diet-induced obese C57BL/6J mice. J Ethnopharmacol. 2016;178: 238-250.
Yuan L, Bambha K. Bile acid receptors and non-alcoholic fatty liver disease. World J Hepatol. 2015; 7:2811-2818.
Xu X, Lu L, Dong Q, Li X, et al. Research advances in the relationship between non-alcoholic fatty liver disease and atherosclerosis. Lipids Health Dis. 2015;14:158.
Yang Y, Li W, Liu Y et al. Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Bio chem. 2014;25:1207-1217.
Maity SG, Mandal AK. A clinical comparative study to evaluate the efficacy and safety of Liv.52 DS tablets in Non-Alcoholic Steatohepatitis (NASH). World J Pharm Res. 2015(4);7:388-414.
Evaluation of safety and efficacy of a Polyherbal formulation Liv.52 DS is effective and safe in management of Non-Alcoholic Steatohepatitis (NASH): An open clinical study. Int J Curr. 2014;2(9):305-316.
Vidyashankar S, Sandeep Varma R, Prahlad S Patki. Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol in Vitro. 2013;27:945–953.
Vidyashankar S, Sharath Kumar L, Barooah V, et al. Liv.52 up-regulates cellular antioxidants and increase glucose uptake to circumvent oleic acid induced hepatic steatosis in HepG2 cells. Phytomed. 2012;19:1156– 1165.
Das K, Kar P. Non-Alcoholic Steatohepatitis. J Assoc Physicians India. 2005:53:195-199.
Kerkar N. Non-alcoholic steatohepatitis in children. Pediatr Transplantation. 2004;8:613-618.
Seela R, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol. 2005; 42:2-12.
Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45(3):269-278.
Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297-2307.
Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients with Non-alcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-315.
Gadgoli C, Mishra SH. Antihepatotoxic activity of p-methoxy benzoic acid from Capparis spinosa. J Ethnopharmacol. 1999;66(2):187–192.
Mantawy MM, Hamed MA, Sammour EM, Sanad M. Influence of Capparis spinosa and Acacia arabica on certain biochemical haemolymph parameters of Biomphalaria alexandrina. J Egyptian Society Parasitol. 2004;34(2):659–677.
Asolkar LV, Kakkar KK, Chopra IC. Capparis spinosa: Glossary of Indian Medicinal Plants with Active Principles. Second supplement, Part I (A–K), (1965–1981),
Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv.52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach. Phytomed. 2005;12(9):619–624.
Germano MP, Pasquale DR, D'Angelo V, et al. Evaluation of extracts and isolated fraction from Capparis spinosa L. buds as an antioxidant source. J Agri Food Chem. 2002;50(5):1168–1171.
Amirghofran Z, Azadbakht M, Karimi MH. Evaluation of the immunomodulatory effects of five herbal plants. J Ethnopharmacol. 2000;72(1–2):167–172.
Kim JH, Mun YJ, Woo WH, et al. Effects of the ethanol extract of Cichorium intybus on the immunotoxicity by ethanol in mice. Intl Immunol. 2002;2(6):733–744.
Gazzani G, Daglia M, Papetti A, Gregotti C. In vitro and ex vivo anti- and prooxidant components of Cichorium intybus. J Pharmaceut Biomed Analysis. 2000;23(1):127-133.
Son YO, Kim J, Lim JC, Chung Y, Chung GH, Lee JC. Ripe fruit of Solanum nigrum L. inhibits cell growth and induces apoptosis in MCF-7 cells. Food Chem Toxicol. 2003;41(10):1421–1428.
Kyung-Sun Heo, Lim KT. Antioxidative effects of glycoprotein isolated from Solanum nigrum L. J Med Food. 2004;7(3):349–357.
Prashanth Kumar V, Shashidhara S, Kumar MM, Sridhara BY. Cytoprotective role of Solanum nigrum against gentamicin-induced kidney cell (Vero cells) damage in vitro. Fitoterapia. 2001;72(5):481–486.
Ram A, Lauria P, Gupta R, Kumar P, Sharma VN. Hypocholesterolaemic effects of Terminalia arjuna tree bark. J Ethnopharmacol. 1997;55(3):165–169.
Manna P, Sinha M, Sil PC. Aqueous extract of Terminalia arjuna prevents carbon tetrachloride induced hepatic and renal disorders. BMC Complement Alternative Med. 2006;6:33.
Munasinghe TC, Seneviratne CK, Thabrew MI, Abeysekera AM. Antiradical and antilipoperoxidative effects of some plant extracts used by Sri Lankan traditional medical practitioners for cardioprotection. Phytotherapy Res. 2001;15(6):519–523.
Ali A, Kaur G, Hayat K, Ali M, Ather M. A novel naphthanol glycoside from Terminalia arjuna with antioxidant and nitric oxide inhibitory activities. Pharmazie. 2003;58(12):932–934.
Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia arjuna Linn. Antiviral Res. 2002;55(3):447–455.
Samy PR, Ignacimuthu S, Sen A. Screening of 34 Indian medicinal plants for antibacterial properties. J Ethnopharmacol. 1998;62(2):173–182.
Bin-Hafeez B, Ahmad I, Haque R, Raisuddin S. Protective effect of Cassia occidentalis L. on cyclophosphamide-induced suppression of humoral immunity in mice. J Ethnopharmacol. 2001;75(1):13–18.
Jafri MA, Jalis Subhani M, Javed K, Singh S. Hepatoprotective activity of leaves of Cassia occidentalis against paracetamol and ethyl alcohol intoxication in rats. J Ethnopharmacol. 1999;66(3):355–361.
Yaeesh S, Jamal Q, Khan AU, Gilani AH. Studies on hepatoprotective, antispasmodic, and calcium antagonist activities of the aqueous-methanol extract of Achillea millefolium. Phytotherapy Res. 2006;20(7):546–551.
Lin LT, Liu LT, Chiang LC, Lin CC. In vitro anti-hepatoma activity of fifteen natural medicines from Canada. Phytotherapy Res. 2002;16(5):440–444.
Sehrawat A, Sultana S. Tamarix gallica ameliorates thioacetamide-induced hepatic oxidative stress and hyperproliferative response in Wistar rats. J Enzyme Inhib Med Chem. 2006;21(2):215–223.
Kanase A, Patil S, Thorat B. Curative effects of Mandura Bhasma on liver and kidney of albino rats after induction of acute hepatitis by CCl4. Indian J Exp Biol. 1997;35(7): 754–764.
Mandura B. The Ayurvedic Formulary of India, Volume-I, Ministry of Health and Family Welfare; Department of ISM & H, Government of India: 613-615.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
